170 related articles for article (PubMed ID: 28362634)
1. Site-selective conjugation of an anticoagulant aptamer to recombinant albumins and maintenance of neonatal Fc receptor binding.
Schmøkel J; Voldum A; Tsakiridou G; Kuhlmann M; Cameron J; Sørensen ES; Wengel J; Howard KA
Nanotechnology; 2017 May; 28(20):204004. PubMed ID: 28362634
[TBL] [Abstract][Full Text] [Related]
2. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
[TBL] [Abstract][Full Text] [Related]
3. A new class of recombinant human albumin with multiple surface thiols exhibits stable conjugation and enhanced FcRn binding and blood circulation.
Schelde KK; Nicholls K; Dagnæs-Hansen F; Bunting K; Rawsthorne H; Andersen B; Finnis CJA; Williamson M; Cameron J; Howard KA
J Biol Chem; 2019 Mar; 294(10):3735-3743. PubMed ID: 30602565
[TBL] [Abstract][Full Text] [Related]
4. Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants.
Petersen SS; Kläning E; Ebbesen MF; Andersen B; Cameron J; Sørensen ES; Howard KA
Mol Pharm; 2016 Feb; 13(2):677-82. PubMed ID: 26654692
[TBL] [Abstract][Full Text] [Related]
5. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs.
Viuff D; Antunes F; Evans L; Cameron J; Dyrnesli H; Thue Ravn B; Stougaard M; Thiam K; Andersen B; Kjærulff S; Howard KA
J Control Release; 2016 Feb; 223():22-30. PubMed ID: 26699424
[TBL] [Abstract][Full Text] [Related]
6. Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin.
Schmidt EGW; Hvam ML; Antunes F; Cameron J; Viuff D; Andersen B; Kristensen NN; Howard KA
J Biol Chem; 2017 Aug; 292(32):13312-13322. PubMed ID: 28637874
[TBL] [Abstract][Full Text] [Related]
7. An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications.
Kuhlmann M; Hamming JBR; Voldum A; Tsakiridou G; Larsen MT; Schmøkel JS; Sohn E; Bienk K; Schaffert D; Sørensen ES; Wengel J; Dupont DM; Howard KA
Mol Ther Nucleic Acids; 2017 Dec; 9():284-293. PubMed ID: 29246307
[TBL] [Abstract][Full Text] [Related]
8. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn).
Sand KM; Bern M; Nilsen J; Dalhus B; Gunnarsen KS; Cameron J; Grevys A; Bunting K; Sandlie I; Andersen JT
J Biol Chem; 2014 Dec; 289(50):34583-94. PubMed ID: 25344603
[TBL] [Abstract][Full Text] [Related]
9. FcRn binding properties of an abnormal truncated analbuminemic albumin variant.
Andersen JT; Daba MB; Sandlie I
Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594
[TBL] [Abstract][Full Text] [Related]
10. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
[TBL] [Abstract][Full Text] [Related]
11. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.
Andersen JT; Daba MB; Berntzen G; Michaelsen TE; Sandlie I
J Biol Chem; 2010 Feb; 285(7):4826-36. PubMed ID: 20018855
[TBL] [Abstract][Full Text] [Related]
12. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
[TBL] [Abstract][Full Text] [Related]
13. Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics.
Bajardi-Taccioli A; Blum A; Xu C; Sosic Z; Bergelson S; Feschenko M
Mol Immunol; 2015 Oct; 67(2 Pt B):616-24. PubMed ID: 26254986
[TBL] [Abstract][Full Text] [Related]
14. Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling.
Merten H; Brandl F; Zimmermann M; Schaefer JV; Irpinio L; Sand KMK; Nilsen J; Andersen JT; Zangemeister-Wittke U; Plückthun A
Eur J Pharm Biopharm; 2021 Oct; 167():104-113. PubMed ID: 34303832
[TBL] [Abstract][Full Text] [Related]
15. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.
Andersen JT; Pehrson R; Tolmachev V; Daba MB; Abrahmsén L; Ekblad C
J Biol Chem; 2011 Feb; 286(7):5234-41. PubMed ID: 21138843
[TBL] [Abstract][Full Text] [Related]
16. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.
Andersen JT; Cameron J; Plumridge A; Evans L; Sleep D; Sandlie I
J Biol Chem; 2013 Aug; 288(33):24277-85. PubMed ID: 23818524
[TBL] [Abstract][Full Text] [Related]
17. Albumin and its application in drug delivery.
Sleep D
Expert Opin Drug Deliv; 2015 May; 12(5):793-812. PubMed ID: 25518870
[TBL] [Abstract][Full Text] [Related]
18. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.
Andersen JT; Dalhus B; Viuff D; Ravn BT; Gunnarsen KS; Plumridge A; Bunting K; Antunes F; Williamson R; Athwal S; Allan E; Evans L; Bjørås M; Kjærulff S; Sleep D; Sandlie I; Cameron J
J Biol Chem; 2014 May; 289(19):13492-502. PubMed ID: 24652290
[TBL] [Abstract][Full Text] [Related]
19. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.
Haraya K; Tachibana T; Nanami M; Ishigai M
Xenobiotica; 2014 Dec; 44(12):1127-34. PubMed ID: 25030041
[TBL] [Abstract][Full Text] [Related]
20. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.
Chia J; Louber J; Glauser I; Taylor S; Bass GT; Dower SK; Gleeson PA; Verhagen AM
J Biol Chem; 2018 Apr; 293(17):6363-6373. PubMed ID: 29523681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
